Future of the Nephrology Drugs Market: Trends, Innovations, and Key Forecasts Through 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Nephrology Drugs Market Size Growth Forecast: What to Expect by 2025?
The market for nephrology drugs has seen consistent growth in the past few years. The sector, with a value of $16.88 billion in 2024, is projected to increase to $17.69 billion in 2025, experiencing a compound annual growth rate (CAGR) of 4.8%. The previous growth can be linked to the escalating rates of chronic kidney diseases (CKD), advancements in the development of medications, heightened awareness and diagnoses, initiatives by the government and amendments to healthcare policies, and the rising incidence of diabetes.

How Will the Nephrology Drugs Market Size Evolve and Grow by 2029?
Anticipated to experience robust growth in the forthcoming years, the nephrology drugs market is projected to soar to "$22.61 billion by 2029, with a compound annual growth rate (CAGR) of 6.3%. This projected increase during the forecast period could be a result of the rise of new therapies and drug innovations, personalized medicine and treatment tactics, a boost in healthcare expenditure, and the adoption of telehealth and remote patient monitoring systems. Other key trends predicted for the forecast period include an increase in collaborations and partnerships, advancements in dialysis technology, development in treatment methods, a growing focus on prompt diagnosis and intervention, and the incorporation of technology in nephrology management.

View the full report here:
https://www.thebusinessresearchcompany.com/report/nephrology-drugs-global-market-report

What Drivers Are Propelling the Growth of Nephrology Drugs Market Forward?
The increasing cases of chronic kidney disease (CKD) are anticipated to fuel the progression of the nephrology drugs market. CKD entails kidney damage that leads to the organ's reduced ability to effectively filter blood due to a protracted period of injury, causing waste materials to accumulate in the body. Nephrology drugs are extensively utilized to treat chronic kidney disease, improving kidney functionality while slowing down the disease to prevent further bodily harm, and these elements are propelling the growth of the nephrology drug market. For example, in July 2022, data from the Centers for Disease Control and Prevention (CDC), a US-based health protection agency, revealed that over 37 million people in the US were diagnosed with CKD, especially prevalent in individuals aged 65 years or older (38 percent). In addition, The Kidney Foundation of Canada, a Canada-based non-profit organization, reported that 4 million Canadians are living with kidney diseases, with diabetic patients accounting for 35 percent as the primary cause of kidney failure. These statistics are predicted to increase in the coming years, thus the escalating morbidity of chronic kidney disease is steering the upward trajectory of the nephrology drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10076&type=smp

What Trends Will Shape the Nephrology Drugs Market Through 2029 and Beyond?
The trend of product innovation is taking center stage in the nephrology medication market, with leading companies introducing novel drugs and products to maintain their market shares. For instance, in March 2022, Zydus Lifesciences Limited, a pharmaceutical company based in India, unveiled Oxemia (desidustat), a new treatment for chronic kidney disease (CKD). This novel oral drug, a small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, offers a viable therapeutic alternative for anemia treatment and has received the Indian Drug Controller General's approval. Having exhibited impressive safety features during Phase III clinical trials, it is known to effectively downregulate hepcidin, improve iron mobilization, and lower LDL-C in CKD patients. Furthermore, its affordability and potential to improve patients' quality of life might reduce the overall disease burden.

What Are the Key Segments in the Nephrology Drugs Market?
The nephrology drugs market covered in this report is segmented -

1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)
2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa
3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics
4) By ACE Inhibitors: Lisinopril, Enalapril
5) By Antidiabetic Agents: Metformin, Insulin
6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10076&type=smp

Who Are the Key Players Shaping the Nephrology Drugs Market's Competitive Landscape?
Major companies operating in the nephrology drugs market include AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc

What Geographic Markets Are Powering Growth in the Nephrology Drugs Market?
North America was the largest region in the nephrology drug market in 2024.Europe will be the second-largest growing region in the nephrology drug market in 2024. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10076

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.